Emergent BioSolutions
Emergent BioSolutions (NYSE: EBS) is a public biodefense and specialty life sciences company that develops, manufactures, and delivers medical countermeasures for biological threats and opioid overdose emergencies to government agencies, healthcare providers, and commercial customers in more than 20 countries.
- Company typePublic
- Founded1997
- HeadquartersGaithersburg, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Emergent BioSolutions does
Emergent BioSolutions is a publicly traded specialty life sciences and biodefense company (NYSE: EBS), founded in 1997 and headquartered in Gaithersburg, Maryland, with approximately 900 employees across the United States, Canada, Ireland, and the United Kingdom. The company operates two primary product segments plus a CDMO business: a Commercial Products portfolio led by NARCAN Nasal Spray 4mg (the first FDA-approved over-the-counter naloxone, distributed over 85 million times across North America) and KLOXXADO 8mg; a Medical Countermeasures portfolio covering ACAM2000 (smallpox and mpox vaccine), BioThrax and CYFENDUS (anthrax vaccines), BAT (botulism antitoxin), ANTHRASIL and raxibacumab (anthrax treatments), Ebanga (Ebola therapeutic), TEMBEXA (smallpox antiviral), and CNJ-016/VIGIV (vaccinia immune globulin); and Strategic Manufacturing Partnerships providing end-to-end process development, scale-up, technology transfer, and clinical/commercial manufacturing for biotech clients.
The underlying technology centers on specialized manufacturing of live attenuated virus vaccines and complex biologics in high-biosafety facilities, particularly at the Winnipeg, Canada full-lifecycle site and the Lansing, Michigan site, with CDMO capabilities also in Canton, Massachusetts. Revenue is generated through government procurement contracts (BARDA, ASPR, U.S. Department of War, Government of Canada, plus international health authorities), commercial OTC and retail sales of NARCAN/KLOXXADO (including the NARCANDirect community program channel), and CDMO services agreements such as the SAB Biotherapeutics and Substipharm Biologics deals. FY2025 revenue was $742.9M (down 29% year-over-year) with FY2026 guidance of $720-760M; the company returned to net profitability of $52.6M in 2025 while reducing net debt 49% to $384M and net leverage to 1.9x.
Emergent BioSolutions firmographics
Firmographics- Name
- Emergent BioSolutions
- Legal name
- Emergent BioSolutions Inc.
- Website
- https://emergentbiosolutions.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Emergent BioSolutions (NYSE: EBS) is a public biodefense and specialty life sciences company that develops, manufactures, and delivers medical countermeasures for biological threats and opioid overdose emergencies to government agencies, healthcare providers, and commercial customers in more than 20 countries.
- Ownership category
- akta.pro rank
Emergent BioSolutions industry classification
Industry- Product category
- Biodefense Pharmaceuticals & Medical Countermeasures
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)
- akta.pro secondary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
Where Emergent BioSolutions is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Emergent BioSolutions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Government Biodefense Contracts: Medical countermeasures products sold to U.S. and international governments including smallpox vaccines, anthrax treatments, botulism antitoxins, and Ebola therapeutics. Revenue from government procurement contracts which can be lumpy and dependent on government funding cycles.
- Commercial Opioid Products: NARCAN Nasal Spray 4mg and KLOXXADO Nasal Spray 8mg sold commercially. NARCAN became over-the-counter in 2023. Revenue from community programs, government procurement, and retail distribution.
- Contract Manufacturing Services: End-to-end development and manufacturing services for biotech firms including SAB Biotherapeutics (SAB-142), Substipharm Biologics (IMOJEV Japanese Encephalitis vaccine). Provides process development, scale-up, technology transfer, clinical and commercial manufacturing from Winnipeg and Canton facilities.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Emergent BioSolutions product offering
Product offeringCore offering
Emergent BioSolutions develops, manufactures, and supplies a portfolio of FDA-approved medical countermeasures against biological threats (smallpox, mpox, anthrax, botulism, Ebola) and commercial opioid overdose products (NARCAN® and KLOXXADO® nasal sprays), distributed primarily to U.S. and international government agencies and through retail channels. The company also operates a contract development and manufacturing organization (CDMO) providing end-to-end process development, scale-up, technology transfer, and cGMP clinical and commercial manufacturing for biotech partners.
Product overview
Emergent BioSolutions is a global specialty life sciences company focused on public health threats. The company operates two primary business segments: (1) Commercial Products including NARCAN® Nasal Spray 4 mg (first FDA-approved OTC naloxone) and KLOXXADO® 8 mg for opioid overdose emergencies; and (2) Medical Countermeasures including ACAM2000® (smallpox/mpox vaccine), BioThrax® and CYFENDUS® (anthrax vaccines), BAT® (botulism antitoxin), ANTHRASIL® and raxibacumab (anthrax treatments), Ebanga® (Ebola therapeutic), TEMBEXA® (smallpox antiviral), and CNJ-016® (vaccinia immune globulin). The company also operates a Strategic Manufacturing Partnerships CDMO business providing end-to-end development and manufacturing services for biopharma clients from its facilities in the U.S., Canada, Ireland, and the United Kingdom.
Differentiator
Problem solved
Functional benefit
Brands
- NARCAN: NARCAN Nasal Spray 4mg - FDA-approved over-the-counter naloxone product for opioid overdose emergency treatment
- KLOXXADO
- ACAM2000
- BioThrax
- BAT
- CYFENDUS
- Ebanga
- TEMBEXA
Products and services
- NARCAN® Nasal Spray 4 mg First FDA-approved, over-the-counter 4 mg naloxone HCl nasal spray for the emergency treatment of opioid overdose. Distributed to federal/state leaders, community organizations, harm reduction groups, law enforcement, first responders, and retail consumers.
- NARCAN® Nasal Spray Multipacks (6-count and 24-count) Bulk multipack configurations of NARCAN® 4 mg nasal spray (6-count and 24-count) designed for community organizations, harm reduction programs, and large-scale distribution operations. Available via the NARCANDirect® ordering platform.
- NARCAN® Nasal Spray Carrying Case FDA-approved carrying case accessory for NARCAN® Nasal Spray, designed to enable convenient carrying and quick access during opioid overdose emergencies.
- KLOXXADO® Nasal Spray 8 mg 8 mg naloxone HCl nasal spray for the emergency treatment of opioid overdose, providing a higher-dose option compared to NARCAN® 4 mg.
- ACAM2000® (Smallpox and Mpox Vaccine, Live) Smallpox and mpox (vaccinia) live vaccine for prevention of smallpox and mpox disease in individuals at high risk for infection. Licensed in the U.S., Singapore, Saudi Arabia, Australia, and Canada.
- BioThrax® (Anthrax Vaccine Adsorbed) Anthrax vaccine adsorbed for pre-exposure and post-exposure prophylaxis of anthrax disease. Approved in the U.S., Canada, Germany, and France.
- CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) Adjuvanted anthrax vaccine for post-exposure prophylaxis of anthrax disease, providing enhanced immune response compared to non-adjuvanted formulations.
- BAT® (Botulism Antitoxin Heptavalent) Heptavalent botulism antitoxin derived from equine sources, neutralizing toxins types A through G. Used for treatment of foodborne, wound, and infant botulism.
- ANTHRASIL® (Anthrax Immune Globulin Intravenous) Human anthrax immune globulin intravenous product for treatment of inhalational anthrax in combination with antibiotics.
- raxibacumab injection Fully human monoclonal antibody targeting Bacillus anthracis protective antigen, used for treatment of inhalational anthrax.
- Ebanga® (ansuvimab-zykl) Monoclonal antibody therapeutic for treatment of Ebola virus disease in adults and children. Marketed and distributed by Emergent under agreement with Ridgeback Biotherapeutics.
- TEMBEXA® (brincidofovir) First FDA-approved oral antiviral for smallpox, approved for all ages. DNA polymerase inhibitor with broad orthopoxvirus activity. Rights acquired from Chimerix in 2022.
- CNJ-016® / VIGIV (Vaccinia Immune Globulin Intravenous) Human vaccinia immune globulin intravenous product for treatment of complications from smallpox vaccination.
- Strategic Manufacturing Partnerships (CDMO Services) Contract development and manufacturing organization (CDMO) services leveraging specialized in-house capabilities to support biopharma innovators, governments, and NGOs with drug development and manufacturing needs. Services include process development, scale-up, technology transfer, clinical manufacturing, and commercial manufacturing of monoclonal antibodies, recombinant proteins, and other complex biologics.
Quantifiable outcome
- 85+ million doses of NARCAN distributed across North America over 10 years
- +2 more outcomes
Companies that use Emergent BioSolutions
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Emergent BioSolutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Emergent BioSolutions partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship, minor and core.
- Victoria's Voice FoundationflagshipPresenting sponsor of National Naloxone Awareness Day on June 6. Partnership supports 'Shine. Wear. Share. Care.' Campaign distributing naloxone products and educational materials to communities.
- Davis Schneider (Toronto Blue Jays)minorBaseball player partnership for opioid awareness. Schneider became paid spokesperson following 2020 death of his brother from opioid overdose. Partnership addresses Canada's opioid poisoning crisis.
- SAB BiotherapeuticscoreMaster Manufacturing Services Agreement for SAB-142, Emergent's lead clinical-stage candidate for autoimmune Type 1 Diabetes. Emergent provides end-to-end drug substance and drug product manufacturing services from its Winnipeg, Manitoba facility. Five-year agreement with $36 million contingent on regulatory approval milestones. Total deal valued at approximately $50 million.
- Substipharm Biologicscore$34.5 million agreement to manufacture drug substance for IMOJEV Japanese Encephalitis vaccine at Emergent's Canton, Massachusetts facility. Emergent will also serve as exclusive distributor to U.S. government following potential FDA regulatory approval.
- British Columbia Provincial Health Services AuthoritycorePartnership to supply NARCAN Nasal Spray for the expanded BC Take-Home Naloxone Program. $18 million CAD investment by B.C. government extending the program that distributed 60,000 kits since pilot launch in 2024.
- Khushi BabyminorDigital health nonprofit partnership through Emergent GIVES corporate social responsibility program. Supports CHIP platform powering India's digital health infrastructure and community health worker systems.
- Last Mile HealthminorNonprofit organization partnership to advance public health, focused on saving lives in underserved communities.
- Ridgeback BiotherapeuticscoreAgreement for Ebanga (ansuvimab-zykl) treatment for Ebola. Emergent markets and distributes the product which is a trademark of Ridgeback Biotherapeutics.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
Emergent BioSolutions competitors and assessment
Company assessmentDirect peers
- Bavarian Nordic: Bavarian Nordic directly competes with Emergent in smallpox/mpox vaccines (JYNNEOS/IMVANEX) and acquired Emergent's travel health business in 2023. Both companies serve biodefense government customers with live attenuated virus vaccines for high-threat pathogens.
- SIGA Technologies: SIGA Technologies is a direct competitor in smallpox therapeutics with TPOXX (tecovirimat), competing against Emergent's TEMBEXA (brincidofovir) and ACAM2000 vaccine in the U.S. government biodefense market. Both companies sell primarily to BARDA/ASPR stockpiles.
- Chimerix: Chimerix originally developed TEMBEXA (brincidofovir), the smallpox antiviral that Emergent acquired in 2022. Both focus on antiviral therapeutics for high-threat pathogens and government biodefense procurement.
Broad incumbents
- Catalent: Catalent is a major CDMO offering biologics manufacturing and fill-finish services that competes with Emergent's Strategic Manufacturing Partnerships business. Both provide contract development and manufacturing services for biopharma clients, though Catalent operates at a much larger scale.
- Lonza Group: Lonza is one of the world's largest CDMOs offering biologics and vaccine manufacturing services comparable to Emergent's Winnipeg and Canton facilities. Both compete for contract manufacturing of complex biologics, vaccines, and monoclonal antibodies.
- Sanofi: Sanofi is a global vaccines manufacturer that previously sold its smallpox vaccine business to Emergent in 2017. Both produce vaccines and biologics at industrial scale and compete for government public health contracts in multiple geographies.
- GSK: GSK is a global pharmaceutical and vaccines company with a comparable biodefense-relevant portfolio including travel and endemic vaccines. Both companies supply vaccines to governments and have CDMO-adjacent biologics manufacturing capabilities.
Emerging players
- Moderna: Moderna is an emerging player in pandemic preparedness vaccines (mRNA platform) that competes with Emergent for government pandemic preparedness contracts and BARDA funding. Both companies developed COVID-era biodefense capabilities.
- Novavax: Novavax is a vaccine developer with comparable government biodefense positioning (NVX-CoV2373 COVID vaccine). Both companies serve public health agencies and have vaccine adjuvanting capabilities (Matrix-M vs CYFENDUS).
- Ridgeback Biotherapeutics: Ridgeback Biotherapeutics is a partner/peer that developed Ebanga (ansuvimab-zykl) Ebola therapeutic which Emergent distributes. Both are focused on infectious disease therapeutics for outbreaks and biodefense applications.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Emergent BioSolutions social profiles
Digital presenceEmergent BioSolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emergent BioSolutions leadership team
Management profileNumber of profiles
Profiles8 records
Emergent BioSolutions subsidiaries and ownership
Company hierarchySubsidiaries1 record
Emergent BioSolutions funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emergent BioSolutions M&A and investment
M&A and investmentM&A6 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emergent BioSolutions
What does Emergent BioSolutions do?
Emergent BioSolutions develops, manufactures, and supplies a portfolio of FDA-approved medical countermeasures against biological threats (smallpox, mpox, anthrax, botulism, Ebola) and commercial opioid overdose products (NARCAN® and KLOXXADO® nasal sprays), distributed primarily to U.S. and international government agencies and through retail channels. The company also operates a contract development and manufacturing organization (CDMO) providing end-to-end process development, scale-up, technology transfer, and cGMP clinical and commercial manufacturing for biotech partners.
Is Emergent BioSolutions a public or private company?
Emergent BioSolutions is a public company. It is classified as public and is currently operating.
When was Emergent BioSolutions founded?
Emergent BioSolutions was founded in 1997. It employs 501 to 1,000 people.
Where is Emergent BioSolutions based?
Emergent BioSolutions is headquartered in Gaithersburg, United States, in the North America region.
How does Emergent BioSolutions make money?
Three revenue lines are on record. Government Biodefense Contracts are the primary driver. The others are commercial Opioid Products and contract Manufacturing Services.
Who are Emergent BioSolutions's main competitors?
Direct peers on record are Bavarian Nordic, SIGA Technologies and Chimerix. Broad incumbents are Catalent, Lonza Group, Sanofi and GSK. Emerging players are Moderna, Novavax and Ridgeback Biotherapeutics.
Does Emergent BioSolutions have an API?
No public API is recorded for Emergent BioSolutions.
What industry is Emergent BioSolutions in?
Emergent BioSolutions's product category is Biodefense Pharmaceuticals & Medical Countermeasures. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2836.